Vivimed Labs.
NSE: VIVIMEDLAB · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Vivimed Labs.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Vivimed Labs is an Indian pharmaceutical company established in 1988 that operates across Active Pharmaceutical Ingredients (APIs), CDMO Finished Dosage Formulations, and specialty chemicals. The company also maintains a presence in the retail branded formulation market.
Business Model
The company generates revenue through the manufacturing and supply of pharmaceutical ingredients and specialty chemicals, alongside providing contract development and manufacturing services. It also markets its own branded formulations in the retail sector.
Management Commentary
Management has recently sought shareholder approval to initiate a pre-packaged insolvency resolution process under the Insolvency and Bankruptcy Code, 2016, reflecting significant financial distress.
Growth Outlook
The company's near-term outlook is dominated by the proposed insolvency resolution process, which creates substantial uncertainty regarding future operational growth and business continuity.
Key Risks
- Insolvency Risk. The initiation of a pre-packaged insolvency resolution process poses a severe threat to the company's going-concern status and operational stability.
- Regulatory Compliance. As a pharmaceutical manufacturer, the company faces stringent regulatory oversight where any failure to meet quality standards could lead to product recalls or facility shutdowns.
- Financial Liquidity. The company faces significant liquidity constraints that may hinder its ability to procure raw materials and maintain manufacturing operations.
- Market Competition. The highly competitive nature of the API and specialty chemicals sector puts pressure on margins and market share, particularly for a company undergoing financial restructuring.
Start your research today
Unlock AI insights, financials, peers and live data on Vivimed Labs. and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Vivimed Labs.VIVIMEDLAB | ₹44 Cr | — | — | — | -218.0% | — | — | — |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Mar 2026
Financials
Vivimed Labs.
NSE: VIVIMEDLAB · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Vivimed Labs.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Vivimed Labs is an Indian pharmaceutical company established in 1988 that operates across Active Pharmaceutical Ingredients (APIs), CDMO Finished Dosage Formulations, and specialty chemicals. The company also maintains a presence in the retail branded formulation market.
Business Model
The company generates revenue through the manufacturing and supply of pharmaceutical ingredients and specialty chemicals, alongside providing contract development and manufacturing services. It also markets its own branded formulations in the retail sector.
Management Commentary
Management has recently sought shareholder approval to initiate a pre-packaged insolvency resolution process under the Insolvency and Bankruptcy Code, 2016, reflecting significant financial distress.
Growth Outlook
The company's near-term outlook is dominated by the proposed insolvency resolution process, which creates substantial uncertainty regarding future operational growth and business continuity.
Key Risks
- Insolvency Risk. The initiation of a pre-packaged insolvency resolution process poses a severe threat to the company's going-concern status and operational stability.
- Regulatory Compliance. As a pharmaceutical manufacturer, the company faces stringent regulatory oversight where any failure to meet quality standards could lead to product recalls or facility shutdowns.
- Financial Liquidity. The company faces significant liquidity constraints that may hinder its ability to procure raw materials and maintain manufacturing operations.
- Market Competition. The highly competitive nature of the API and specialty chemicals sector puts pressure on margins and market share, particularly for a company undergoing financial restructuring.
Start your research today
Unlock AI insights, financials, peers and live data on Vivimed Labs. and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026